Maxair inhalers will not be made, dispensed, or sold in the United States in their current form after December 31, 2013. Maxair contains chlorofluorocarbons (CFCs), chemicals that deplete the ozone layer. The U.S. Food and Drug Administration (FDA) has set this final date for the medication in order to comply with the Montreal Protocol on Substances That Deplete the Ozone Layer. The manufacturer of Maxair is working on a reformulated, CFC-free version, although it is not yet clear when that product will be available to consumers.
Maxair® (pirbuterol acetate) is a prescription medicine licensed to prevent or treat bronchospasms. It comes in a special inhaler that is available in two different sizes, one containing 400 inhalations and the other containing 80 inhalations.
The Maxair Autohaler® is different from traditional inhalers, as it does not release the medication until you inhale through the mouthpiece. Some people use the inhaler only when they need it during an asthma attack, while others use it regularly to help prevent attacks.
You should talk to your healthcare provider before using the Maxair Autohaler if you have diabetes, high blood pressure, an irregular heart rhythm, or congestive heart failure.
(Click Maxair for information on how the medication works, to learn how to use the inhaler, and to find out what side effects may occur with treatment.)